Biomarker hub
KRAS
Trials and papers mentioning KRAS.
Trials mentioning krasView all trials
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ACTIVE_NOT_RECRUITING · Phase not listed
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
RECRUITING · Phase not listed
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
RECRUITING · Phase not listed
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RECRUITING · Phase not listed
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RECRUITING · Phase not listed
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
RECRUITING · Phase not listed
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase not listed
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RECRUITING · Phase not listed
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase not listed
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
TERMINATED · Phase not listed
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
RECRUITING · Phase not listed
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
AVAILABLE · Phase not listed
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase not listed
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
AVAILABLE · Phase not listed
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
RECRUITING · Phase not listed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
RECRUITING · Phase not listed
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
RECRUITING · Phase not listed
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase not listed
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
TERMINATED · Phase not listed
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
ACTIVE_NOT_RECRUITING · Phase not listed
Papers mentioning krasView all papers